Loading...
 
Mediterr J Rheumatol 2017;28(1):48-61
The use of Canakinumab in treating resistant gouty disease in patients with limited therapeutic options: The experience of the Rheumatology Clinic of Asklipeion General Hospital of Voula, Greece
Authors Information
Asklipeion General Hospital of Voula, Athens, Greece
References
  1. Qing Y, Zhang Q, Zhou J. Innate immunity functional gen polymorphisms and gout susceptibility. Gene 2013;524:412-4.
  2. Martinon F. Mechanisms of uric acid crystal mediated autoinflammation. Immunol Rev 2010;233.1:218-32.
  3. Saag K G, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther 2006;8:S2.
  4. Luk A J, Simkin P A. Epidemiology of Hyperuricemia and Gout. Am J Manag Care 2005;11:S435-S442.
  5. Keenan R, O’Brien W, Lee K. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011;124,155-63.
  6. Suresh E. Diagnosis and management of gout: a rational approach. Postgrad Med J 2005;81:572-9.
  7. Latourte A, Bardin T, Richette P. Prophylaxis for acute gout flares after initiation of urate-lowering therapy. Rheumatology 2014;53:1920-6.
  8. Cavalli G, Dinarello C. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology 2015;54:2134-44.
  9. Schlesinger N, Alten R, Brdin T. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomized, multicenter, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012;71:1839-48.
  10. Schlesinger N. Treatment of Acute Gout. Rheum Dis Clin N Am 2014;329-41.
  11. Dumusc A, So A. Interleukin-1 as a therapeutic target in gout. Curr Opin Rheumatol 2015;27:156-63.
  12. Hirch D, Gnanasakthy A, Lale R, Choi K, Sarkin A.J. Efficacy of canakinumab vs. triamcinolone acetonide according to multiple gouty Arthritis-related health outcomes measures. Int J Clin Pract 2014;68:1503-7.
  13. So A, de Meulemeester M. Canakinumab for the Treatment of Acute Flares in Difficult-to-treat Gouty Arthritis. Arthritis Rheum 2010;62:3064-76.
  14. Alten R, Bardin T, Bloch M, Lheriter K, Machein U, Junge G, et al. FRIO330 Safety and Efficacy of Canakinumab in Frequently Flaring Gouty Arthritis Patients Who are Contraindicated, Intolerant or Unresponsive to Non-Steroidal Anti-Inflammatory Drugs and/or Colchicine: Results from 3 Years Follow-Up. Ann Rheum Dis 2015;74:544. https://doi.org/10.1136/annrheumdis-2015-eular.2199.